AstraZeneca drug Fasenra fails to achieve main goal in COPD trial
AstraZeneca’s first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
The drug is currently approved as an add-on treatment for severe eosinophilic asthma in the United States, the European Union, Japan and several other countries.
Fasenra failed to meet its target in the final-stage trial, named Galathea, this month.
(Reporting By Justin George Varghese in Bengaluru; Editing by David Goodman)
AstraZenecaChronic Obstructive Pulmonary DiseaseClinical TrialCOPD trialdrugeosinophilic asthmaFasenraGalathea
Source : REUTERSNext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd